BRCA1 Cancer Research Results
BRCA1, BReast CAncer gene 1: Click to Expand ⟱
| Source: CGL-Driver Genes |
| Type: TSG |
BRCA1 and BRCA2 are tumor suppressor genes, which, when they function normally, keep tumors from forming.
BRCA1 mutations are associated with an increased risk for:
Breast cancer, including an aggressive form called Triple Negative Breast Cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
BRCA1/BRCA2 are used as clinical biomarker for PARP inhibitor use.
|
Scientific Papers found: Click to Expand⟱
BRCA1↑,
BRCA2↑,
ATM↓,
| - |
in-vitro, |
BC, |
HCC-38 |
|
|
|
- |
in-vitro, |
BC, |
T47D |
|
|
|
BRCA1↑,
TET1↑,
DNMT3A↑, Curcumin downregulates the expression of DNMT1 and upregulates TET1 and DNMT3 in HCC-38 cells
DNMT1↓,
SNCG↓,
miR-29b↓, HCC-38 cells
miR-29b↑, upregulates miR-29b in T47D cells
OS↑, In 2008, a cohort study of breast cancer survivors identified that patients who consistently exercised for greater than 2.5 hours per week following diagnosis had a greater than 60% reduction in the risk of all deaths compared with patients who were
IGF-1↓, Table 1, IGF1 Decreased levels, IGFBP3 Increased levels
IGFBP3↑,
BRCA1↑, BRCA1 Increased expression
BRCA2↑, BRCA2 Increased expression
RAS↓, RAS family oncogenes Suppressed activity
P53↑, P53 Enhanced activity
HSPs↑, Heat shock proteins Enhanced activity
Leptin↓, Leptin Reduced activity
Irisin↓, Irisin Enhanced activity
Resistin↓, Resistin Reduced activity
NK cell↑, NK cells Enhanced activity
CRP↓, C-reactive protein, interleukin-6, TNFα Reduced activity
IL6↓,
TNF-α↓,
PGE1↓, Prostaglandins Reduced activity
COX2↓, Cox-2 Reduced activity
*GSH↑, Glutathione, Catalase and Superoxide dismutase Increased activity
*Catalase↑,
*SOD↑,
*monoA↑, Monoamines Higher levels
*EndoR↑, Endorphins Increased release
*testos↑, testosterone increases immediately after vigorous exercise in some but not all studies. lasting for 20–60 minutes post-exercise
ROS↑, Physical activity, especially if strenuous, produces reactive oxidative species (ROS)
QoL↑, Adverse cancer-related symptoms, which have been shown to be alleviated by exercise, include fatigue, muscle weakness, thromboembolism, weight gain, loss of bone density, quality of life (QOL), psychological distress, incontinence and sexual dysfunct
BMD↑, the rate of decline in BMD was significantly less in the resistance exercise group, with a greater benefit seen in the aerobic exercise group
BowelM↑, Exercise reduces bowel transit time and ameliorates constipation and its associated abdominal cramps
| - |
in-vitro, |
Pca, |
PC3 |
|
|
|
- |
in-vitro, |
Pca, |
DU145 |
|
|
|
- |
in-vitro, |
Pca, |
LNCaP |
|
|
|
cycD1/CCND1↓, CCND1, CCND2, CCND3
cycE/CCNE↓, CCNE1, CCNE2
CDK2↓,
CDK4/6↓, CDK4, CDK8
E2Fs↓, E2F2, E2F3
PCNA↓,
cDC2↓,
PTEN↑,
MSH2↑,
P21↑,
EP300↑, p300
BRCA1↑,
NF2↑,
TSC1↑,
TGFβR1↑, TGFβR2
P53↑,
RB1↑, Rb
AKT1↓,
cMyc↓,
CDC7↓,
cycF↓, CCNF
CDC16↓,
CUL4B↑, CUL4B, a member of the cullin gene family that is also known to be involved in control of the cell cycle, was significantly up-regulated by quercetin.
CBP↑,
TSC2↑,
HER2/EBBR2↓, erb-2
BCR↓,
TumCCA↑, quercetin significantly inhibited the expression of specific oncogenes and genes controlling G1, S, G2, and M phases of the cell cycle.
chemoPv↑, Our results correlate with those of nutritional studies that support the roles of dietary bioflavonoids as cancer chemopreventive agents.
DNMTs↓, weaker DNMT inhibitory activity than other dietary bioactive components such as EGCG
BRCA1↑, resveratrol treatment, which was associated with BRAC-1 reactivation in MCF-7 cells
HDAC↓, resveratrol is associated with activation of the type III HDAC inhibitors, sirtuin 1 (SIRT1), and p300, in multiple in vitro and in vivo models
SIRT1↑,
p300↓, Significant decreases in the amounts of p300, HDAC1, HDAC3, and HDAC8
survivin↓,
HDAC1↓,
HDAC3↓,
HDAC8↓,
AntiCan↑, Thymoquinone is a natural product with anticancer activity.
Inflam↓, Thymoquinone has been shown to exert anti-inflammatory, antidiabetic, antihypertensive, antimicrobial, analgesic, immunomodulatory, spasmolytic, hepatoprotective, renal-protective, gastroprotective, bronchodilatory, antioxidant and antineoplastic eff
hepatoP↑,
RenoP↑,
BAX↑, Thymoquinone can upregulate proapoptotic genes and proteins, such as Bax/Bak, or downregulate antiapoptotic genes and proteins, such as Bcl-2, Bcl-xL, among others, as well as modulating the caspase pathway
Bak↑,
Bcl-2↓,
Bcl-xL↓,
ROS↑, through the generation of reactive oxygen species (ROS)
P53↑, overexpressed or activated by thymoquinone; for example, p53, PTEN, p21, p27 and breast cancer type 1 susceptibility protein (BRCA1), among others,
PTEN↑,
P21↑,
p27↑,
BRCA1↑,
PI3K↓, (PI3K)/Akt and mitogen-activated protein kinase (MAPK)/ERK, have been found to be inhibited by thymoquinone
Akt↓,
MAPK↓,
ERK↓,
p‑ERK↓, thymoquinone reduces ERK phosphorylation and matrix metalloproteinase (MMP) secretion by downregulating focal adhesion kinase (FAK)
MMPs↓,
FAK↓,
Twist↓, downregulates Twist1 and Zeb1 transcription factors, and thus inhibits epithelial to mesenchymal transition (EMT) and subsequently inhibits cancer metastasis
Zeb1↓,
EMT↓,
TumMeta↓,
angioG↓, thymoquinone can inhibit angiogenesis by interfering with essential steps of neovascularization, such as suppressing proangiogenic vascular endothelial growth factor (VEGF)
VEGF↓,
HDAC↓, HDACs are usually overexpressed in MCF-7 breast cancer cells, and thymoquinone can act as a HDAC inhibitor (HDACi) that potently induces apoptosis through inducing acetylation of histones and inhibiting deacetylation of histones.
Maspin↑, thymoquinone reactivates HDAC target genes (p21 and Maspin), inducing the upregulation of Bax
SIRT1↑, thymoquinone can upregulate SIRT1 expression in neonatal rat cardiomyocytes and consequently deacetylates p53; thus, it can act as an apoptosis inducer
DNMT1↓, Collectively, they suggested that thymoquinone induces methylation of DNA via binding with DNMT1 and suppressing its expression,
DNMT3A↓, thymoquinone decreases the expression of some important epigenetic proteins like DNMT1,3A,3B, G9A, HDAC1,4,9, KDM1B, KMT2A,B,C,D,E and UHRF1 in Jurkat cells,
HDAC1↓,
HDAC4↓,
Showing Research Papers: 1 to 6 of 6
* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 6
Pathway results for Effect on Cancer / Diseased Cells:
Redox & Oxidative Stress ⓘ
ROS↑, 2,
Mitochondria & Bioenergetics ⓘ
BCR↓, 1, CDC16↓, 1,
Core Metabolism/Glycolysis ⓘ
AKT1↓, 1, cMyc↓, 1, SIRT1↑, 2,
Cell Death ⓘ
Akt↓, 1, Bak↑, 1, BAX↑, 1, Bcl-2↓, 1, Bcl-xL↓, 1, CBP↑, 1, MAPK↓, 1, p27↑, 1, survivin↓, 1,
Kinase & Signal Transduction ⓘ
CDC7↓, 1, HER2/EBBR2↓, 1, TSC2↑, 1,
Transcription & Epigenetics ⓘ
BowelM↑, 1,
Protein Folding & ER Stress ⓘ
HSPs↑, 1,
DNA Damage & Repair ⓘ
ATM↓, 1, BRCA1↑, 6, BRCA2↑, 2, CUL4B↑, 1, DNMT1↓, 2, DNMT3A↓, 1, DNMT3A↑, 1, DNMTs↓, 1, P53↑, 3, PCNA↓, 1,
Cell Cycle & Senescence ⓘ
CDK2↓, 1, cycD1/CCND1↓, 1, cycE/CCNE↓, 1, cycF↓, 1, E2Fs↓, 1, P21↑, 2, RB1↑, 1, TumCCA↑, 1,
Proliferation, Differentiation & Cell State ⓘ
cDC2↓, 1, EMT↓, 1, EP300↑, 1, ERK↓, 1, p‑ERK↓, 1, HDAC↓, 2, HDAC1↓, 2, HDAC3↓, 1, HDAC4↓, 1, HDAC8↓, 1, IGF-1↓, 1, IGFBP3↑, 1, NF2↑, 1, p300↓, 1, PI3K↓, 1, PTEN↑, 2, RAS↓, 1,
Migration ⓘ
CDK4/6↓, 1, FAK↓, 1, miR-29b↓, 1, miR-29b↑, 1, MMPs↓, 1, MSH2↑, 1, TET1↑, 1, TSC1↑, 1, TumMeta↓, 1, Twist↓, 1, Zeb1↓, 1,
Angiogenesis & Vasculature ⓘ
angioG↓, 1, VEGF↓, 1,
Immune & Inflammatory Signaling ⓘ
COX2↓, 1, CRP↓, 1, IL6↓, 1, Inflam↓, 1, NK cell↑, 1, PGE1↓, 1, Resistin↓, 1, TNF-α↓, 1,
Protein Aggregation ⓘ
SNCG↓, 1,
Hormonal & Nuclear Receptors ⓘ
Irisin↓, 1, Leptin↓, 1,
Clinical Biomarkers ⓘ
BMD↑, 1, BRCA1↑, 6, CRP↓, 1, HER2/EBBR2↓, 1, IL6↓, 1, Maspin↑, 1,
Functional Outcomes ⓘ
AntiCan↑, 1, chemoPv↑, 1, hepatoP↑, 1, OS↑, 1, QoL↑, 1, RenoP↑, 1, TGFβR1↑, 1,
Total Targets: 92
Pathway results for Effect on Normal Cells:
Redox & Oxidative Stress ⓘ
Catalase↑, 1, GSH↑, 1, SOD↑, 1,
Synaptic & Neurotransmission ⓘ
EndoR↑, 1, monoA↑, 1,
Hormonal & Nuclear Receptors ⓘ
testos↑, 1,
Total Targets: 6
Scientific Paper Hit Count for: BRCA1, BReast CAncer gene 1
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:32 State#:% Dir#:2
wNotes=on sortOrder:rid,rpid
Home Page